Frequently asked questions
Clear answers for a field where the details matter.
Regenerative medicine is often discussed as if every treatment is the same. The purpose of this FAQ is to make the categories, evidence, and uncertainties easier to understand.
Stem cells and regenerative medicine
Are all stem-cell treatments the same?
No. Stem-cell therapies differ by cell type, source, donor type, processing, dose, route of delivery, disease target, regulation, and evidence base. Hematopoietic stem-cell transplantation, mesenchymal stromal/stem-cell products, adipose-derived preparations, bone marrow aspirate concentrate, and umbilical-cord-derived products should not be treated as interchangeable.
What is the difference between autologous and allogeneic treatment?
Autologous treatments use material taken from the same patient. Allogeneic treatments use donor-derived cells or tissue products. This distinction matters for immune risk, manufacturing standards, regulatory oversight, availability, cost, and how the treatment can reasonably be studied.
What are MSCs and HSCs?
HSCs, or hematopoietic stem cells, are blood-forming stem cells used in established transplant medicine for selected blood and immune conditions. MSCs, often called mesenchymal stromal or stem cells, are studied for anti-inflammatory, trophic, and tissue-modulating effects, but most MSC indications remain investigational.
Where are stem cells harvested from?
Commonly discussed sources include bone marrow, adipose tissue, peripheral blood after mobilization, and perinatal tissues such as umbilical cord or placenta. Each source produces a different biological product, and the source alone does not prove that a treatment is effective.
Are PRP and PRF stem-cell treatments?
No. Platelet-rich plasma and platelet-rich fibrin are regenerative or orthobiologic treatments, but they are not stem-cell therapies. They use platelet-derived growth factors and fibrin biology rather than transplanted stem cells.
What treatments are already established?
The clearest established stem-cell use is hematopoietic stem-cell transplantation for selected hematological, immune, and oncological conditions. Some tissue-engineered or cell-based products have regulatory approval in specific jurisdictions and indications. Many musculoskeletal, neurological, cardiac, endocrine, and cosmetic claims remain experimental or incompletely proven.
What areas look promising but still need more work?
Active areas include cartilage repair, inflammatory disorders, wound healing, diabetes, cardiac repair, neurodegenerative disease, spinal cord injury, and extracellular vesicle or exosome-based approaches. Promise does not equal proof; durable outcomes, safety, manufacturing consistency, and controlled trials remain essential.
What should patients ask before considering treatment?
Ask what the product is, where it comes from, how it is processed, whether it is regulated for the indication, what evidence supports that specific use, what outcomes are realistic, what risks are known, and how adverse events and follow-up are handled.
How should clinicians use this resource?
Use it as an evidence-orientation tool. It can support journal clubs, patient discussions, teaching, consent conversations, and clinical governance, but it is not a substitute for full-text appraisal, local regulation, or specialist clinical judgment.